Apyx Medical Corporation
APYX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.11 | 0.25 | -0.07 | -1.13 |
| FCF Yield | -33.42% | -6.37% | -26.36% | -2.54% |
| EV / EBITDA | -3.76 | -4.72 | -3.24 | -29.45 |
| Quality | ||||
| ROIC | -34.74% | -22.74% | -59.21% | -26.42% |
| Gross Margin | 61.04% | 64.49% | 65.45% | 69.26% |
| Cash Conversion Ratio | 0.77 | 0.28 | 0.87 | 0.69 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.62% | 2.57% | 17.11% | 19.78% |
| Free Cash Flow Growth | -224.61% | 72.84% | -90.57% | 32.89% |
| Safety | ||||
| Net Debt / EBITDA | -0.42 | 0.28 | 0.43 | 2.20 |
| Interest Coverage | -3.19 | -6.96 | -1,570.80 | -1,444.80 |
| Efficiency | ||||
| Inventory Turnover | 2.48 | 1.87 | 1.30 | 2.20 |
| Cash Conversion Cycle | 213.84 | 239.57 | 366.27 | 260.69 |